Why LLY Stock surged +6.63% Today — RQD Quant Desk Flash

$1,373.70 +6.63% NYSE • Public Delayed / 60s Snapshot

Eli Lilly and Company (LLY) earns a Roarable Rating of B (Buy) with 72/100 RQD Confidence. High-quality cash engine (84% profit margin, 32% return on capital) with steady institutional support. Even if the broader market gets choppy, the company’s underlying cash engine and big-money support put the odds in buyers’ favor.

ROARABLE B • BUY Cap $1.33T
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
RQD QUANT TACHOMETERBUY • B
025507510072
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
5-PILLAR SNOWFLAKE RADARRw B+ · Rk C
Cash (19)Whales (14)SEC (12)Macro (14)CEO (13)
Each axis scored 0–20
12M PRICE TARGET CONE+23% Base Target
$1824 Bull$1690 Base$1473 Bear
🔴 SUNDAY NIGHT PREP • 7:00 PM ET
WHALE OPTIONS TUG-OF-WAR:45% Call Buyers ($5.4M)
55% PutsMax Pain: $1,200.00
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why LLY Stock surged +6.63% Today — RQD Quant Desk Flash

Eli Lilly and Company (LLY) surged +6.63% to $1373.70 as options desks priced 45% call premium vs. 55% put protection around the $1200 max-pain magnet. High-quality cash engine (84% profit margin, 32% return on capital) with steady institutional support.

  • ▸Technical Tape: Trading at 88% of its 52-week range ($809.63 – $1449.68) with RSI-14 at 77.9 (OVERBOUGHT (>70)).
  • ▸Whale Options Positioning: $5.4M in bullish call flow vs. $6.6M in put flow (Put/Call 1.48x, implied earnings swing ±6.8%).
  • ▸Primary SEC / Cross-Feed Trigger: Bottom-Decile Suit (34.5% Hit Rate) Cautious on LLY Despite 19/20 WSG Forensic Fundamentals
Live LLY Headlines & Catalysts
🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher + Senior Cash-Flow & Income Strategist

Cash-Fortress Compounders: Collecting Safe Yield & Upside in LLY & Top A-Rated Leaders

  • ✓12-month Bull/Base/Bear fair-value walkthrough on LLY and its top sector rival
  • ✓The Top 5 Roarable A-Rated cash compounders with heavy executive & 13F accumulation
  • ✓Includes free daily Morning Market Weather & signal upgrade/downgrade dispatch
RQD INSIDER CLUB UPGRADE$49/YEAR
Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?
LLY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +47.15%▲ RESISTANCE BREAKOUT
2026-10-30O $1,286.4H $1,449.7L $1,260.3C $1,417.5VOL 15.63M
RES: $1,364.7SMA50: $1,197.1SMA200: $1,091.2
$1,491.6$1,317.9$1,144.1$970.3$796.6RES $1,364.7$1,417.52026-05-012026-06-122026-07-312026-09-112026-10-30
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LLY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor (#25)
-0.53% YoY Shares

SEC XBRL FY2024 → FY2025: Net share cannibal / buyback tailwind.

Reverse-DCF Expectations Hurdle (#30)
35.5%/yr Implied 5Y Growth

vs. +45.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)
DEVELOPING · Incretin Capacity Base Reclaim

Trigger: $1452.98 • Invalidation: $1349.50

🦋 Documented & Second-Order Butterfly Connections Open Graph →
WST → LLY Confirmed Filing
West Pharmaceutical Services manufactures NovaPure fluoropolymer-coated elastomer plungers and cartridge seals required inside sterile single-dose and multi-dose GLP-1 auto-injector pens.
TMO → LLY Confirmed Filing
Following Novo Holdings acquisition of Catalent fill-finish sites, Eli Lilly and rival GLP-1 developers increasingly rely on Thermo Fisher Patheon sterile fill-finish lines to clear injectable pen bottlenecks.
LLY → NVO Confirmed Filing
Eli Lilly dual GIP/GLP-1 agonist tirzepatide (Zepbound/Mounjaro) demonstrated superior head-to-head weight loss vs. Novo Nordisk semaglutide (Wegovy) in SURMOUNT-5, intensifying PBM rebate competition.

LLY Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Why is LLY stock moving today?

Why LLY Stock surged +6.63% Today — RQD Quant Desk Flash. High-quality cash engine (84% profit margin, 32% return on capital) with steady institutional support.